中廣核礦業(01164.HK)第一季度旗下礦山共生產天然鈾555.9tU 季度計劃完成率108.0%
格隆匯4月21日丨中廣核礦業(01164.HK)公吿,2022年第一季度,集團旗下投資的礦山共生產天然鈾555.9tU,本季度計劃完成率108.0%。其中,集團持股49%哈薩克斯坦合營企業謝米茲拜伊鈾有限合夥企業生產天然鈾205.8tU;而另一持股49%哈薩克斯坦聯營公司礦業公司奧爾塔雷克有限合夥企業生產天然鈾350.1tU。
截至2022年3月31日,集團持有天然鈾1713tU(約445萬磅U3O8),加權平均成本為35.63美元╱磅U3O8;持有已簽訂但尚未交付的天然鈾銷售量3,962tU(約1,030萬磅U3O8),加權平均售價為37.73美元╱磅U3O8。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.